A Novel Approach To Improving Cancer Care
New in-vitro diagnostics are needed to monitor and predict cancer metastasis. This would help stratify patients for optimal treatment and follow-up care. We are developing cancer diagnostics that will give clinicians the power to detect and predict metastasis with high specificity and sensitivity.
New therapeutics for blocking metastatic cancer are important in both early prevention while therapeutic decisions are being made and expanding patient survival. We are working on a new set of blocking molecules that inhibit the ability for the cancer cells to bind and enter the circulation. The diagnostic offers a novel companion diagnostic for this exciting treatment.
With these tests we will redefine the cancer care pathway.
Using non-diluting funds we are entering clinical testing and will be looking for investment later 2022 Q4
Contact us on ryan@MetaGuideX.com
MetaGuideX Management
Dr David Browning
Chair
OBN chair and CEO
CEO Fixed Phage
CEO Oxford Cancer Biomarkers
Amersham International J&J, Philips, NHS.
Dr Ryan Pink
CEO/Co-Founder
Co-inventor
Board member on multiple Oxford healthcare organisations
Biotech consultant for companies like ThermoFisher and Bioline
Clinical researcher €6m Siemens cancer diagnosis tech
Dr Mark Beggs
Advising COO
Experience with Pfizer, Janssen, AstraZeneca and GSK
CEO, UK Biocentre: quadrupled revenue to >£4m pa
Chief Executive, Stratified Medicine Scotland
Advisory team
Prof Susan Brooks, Co-Founder/inventor – Glycoprotein expert and clinical study experience
Prof Dave Carter, Co-Founder/inventor – Exosome expert, ex-UK Exosome Society President, Research dir. Evox Therapeutics
Prof Nigel Groome, SAB – Decades of assay and antibody development. Patented prenatal testing assays totalling a billion tests internationally
Contact us on ryan@metaguidex.com
MetaGuideX Ltd – Company number 12549905